Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund The Boehringer Ingelheim Venture Fund was established in 2010 as an evergreen CVC, growing from an initial €100M allocation to €350M (roughly $400M). The fund has made 70+ investments including fund-in-fund positions, with 40+ currently in the portfolio. Focus areas include immuno-oncology, regenerative medicine, infectious diseases, and digital health. Check sizes run €500K to €15M with a 5-7 year investment horizon. The fund primarily targets pre-clinical asse